Chicago, IL - Almost half of patients with non-ST-elevation acute coronary syndromes (NSTE-ACS) who received enoxaparin (Lovenox, Sanofi-Aventis) were given doses that were either higher or lower than ...
Aug. 18, 2004 — The U.S. Food and Drug Administration (FDA) and Aventis Pharmaceuticals notified healthcare professionals in March of revisions to the precautions section of drug labeling for ...
Princeton, New Jersey, April 25, 2012 – Sandoz today announced the introduction of enoxaparin sodium injection, USP 3 mL vials, a generic version of Sanofi's Lovenox® Injection Multiple-Dose Vials, in ...
DUBLIN--(BUSINESS WIRE)--The "Lovenox - Drug Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering. 'Lovenox Drug Insight, 2018' highlights the drug marketed details and ...
The efficacy of the low molecular weight heparin (LMWH) enoxaparin for anticoagulation in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) is well established, but bleeding ...
(HealthDay)—Once-daily enoxaparin is associated with fewer major bleeds than enoxaparin twice daily in patients with acute venous thromboembolism (VTE), according to a study published online Jan. 25 ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window NEW ORLEANS -- ...
The critically ill, premature patients of neonatal intensive care units are susceptible to venous thrombosis, an adverse event associated with short- and long-term morbidity. Venous thrombosis is ...
(WASHINGTON, April 30, 2004) – Enoxaparin, an anticoagulant, has proven to be an effective preventive measure against stillbirth in pregnant women with hereditary thrombophilia, according to a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback